Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | President | September 24, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date September 24, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 130,504 |
Reported balance
After 2026-09-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-24 · Gift · Disposed 123,407 · Balance 130,504 F1: On September 24, 2026, the reporting person contributed 123,407 shares of BEAM common stock to the Giuseppe Ciaramella Irrevocable Trust - 2026, of which the reporting person's spouse is trustee. The beneficiaries of the trust are the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the securities held by the trust. |
| Common StockSEC Table I · non-derivative | IndirectBy spousal trust | 123,407 |
Reported balance
Holding disclosure · report date 2026-09-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 123,407 F1: On September 24, 2026, the reporting person contributed 123,407 shares of BEAM common stock to the Giuseppe Ciaramella Irrevocable Trust - 2026, of which the reporting person's spouse is trustee. The beneficiaries of the trust are the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the securities held by the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 24, 2026, the reporting person contributed 123,407 shares of BEAM common stock to the Giuseppe Ciaramella Irrevocable Trust - 2026, of which the reporting person's spouse is trustee. The beneficiaries of the trust are the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the securities held by the trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,700 | $88.22 | $149,974.00 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · nonDerivative · entry 11 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,331 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F12 · price: These shares were sold in multiple transactions ranging from $87.80 to $88.67 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 769 | $86.96 | $66,872.24 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · nonDerivative · entry 10 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,031 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F11 · price: These shares were sold in multiple transactions ranging from $86.72 to $87.51 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 6,756 | $86.27 | $582,840.12 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · nonDerivative · entry 9 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F10 · price: These shares were sold in multiple transactions ranging from $85.71 to $86.69 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,049 | $85.16 | $259,652.84 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · nonDerivative · entry 8 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,556 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: These shares were sold in multiple transactions ranging from $84.69 to $85.68 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 8,248 | $84.06 | $693,326.88 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · nonDerivative · entry 7 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,605 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: These shares were sold in multiple transactions ranging from $83.60 to $84.59 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,805 | $83.12 | $233,151.60 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · nonDerivative · entry 6 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,853 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: These shares were sold in multiple transactions ranging from $82.52 to $83.51 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 5,297 | $82.00 | $434,354.00 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · nonDerivative · entry 5 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,658 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: These shares were sold in multiple transactions ranging from $81.52 to $82.51 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 8,809 | $80.97 | $713,264.73 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · nonDerivative · entry 4 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,955 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: These shares were sold in multiple transactions ranging from $80.52 to $81.51 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,510 | $80.12 | $281,221.20 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · nonDerivative · entry 3 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,764 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: These shares were sold in multiple transactions ranging from $79.52 to $80.51 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 2,299 | $79.03 | $181,689.97 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · nonDerivative · entry 2 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,274 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: These shares were sold in multiple transactions ranging from $78.49 to $79.48 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:32 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 43,842 | $1.03 | $45,157.26 |
DisclosureSEC source: 0000899243-21-000138 · doc4.xml · nonDerivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 21:49 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,731 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-20-026911 · doc4.xml · derivative · entry 2 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,444 Underlying: Common Stock · 3,731 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the of the vesting commencement date, February 26, 2018, and the remaining shares shall vest in 36 substantially equal monthly installments thereafter, subject to continued service with BEAM through such dates. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 21:49 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 3,731 | $0.67 | $2,499.77 |
DisclosureSEC source: 0000899243-20-026911 · doc4.xml · nonDerivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 14:07 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 510,893 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003938 · doc4.xml · derivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,893 Underlying: Common Stock · 510,893 shares Expires 2030-02-05 F1 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, February 5, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| February 05, 2020 Filed Sep 21, 2021 22:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 12,978 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0000899243-21-036823 · doc4a.xml · derivative · entry 2 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,978 Underlying: Common Stock · 12,978 shares Expires 2029-02-13 F1 · security: On February 11, 2020, the reporting person filed a Form 4 which inadvertently omitted certain options held by the reporting person on such date (the "Original Form 4"). F4 · derivative.exercise_date: On February 13, 2019, the reporting person was granted an option to purchase 25,957 shares of common stock of the Company. The option award vests (i) fifty percent (50%) upon the Company achieving a certain development milestone related to base editing applications, and (ii) fifty percent (50%) upon the achievement of a closing price hurdle following the Company's IPO (which closing price hurdle has been achieved). The portion of the award subject to satisfaction of the Price Condition is scheduled to vest in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022. Upon the closing of the IPO, vesting of the portion of the option award subject to condition (ii) was tied only to the passage of time and the market price of the Company's securities and thus, 50% of the option award became reportable. The Original Form 4 failed to report the portion of the option award that became reportable upon the closing of the Company's IPO. Read SEC document |
| February 05, 2020 Filed Sep 21, 2021 22:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 27,317 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-21-036823 · doc4a.xml · derivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,317 Underlying: Common Stock · 27,317 shares Expires 2028-05-08 F1 · security: On February 11, 2020, the reporting person filed a Form 4 which inadvertently omitted certain options held by the reporting person on such date (the "Original Form 4"). F2 · derivative.exercise_date: On May 8, 2018, the reporting person was granted an option to purchase 54,635 shares of common stock of Beam Therapeutics Inc. (the "Company"). The option award vests (i) fifty percent (50%) upon the Company achieving a certain development milestone related to base editing applications, and (ii) fifty percent (50%) upon the achievement of a closing price hurdle following the Company's initial public offering ("IPO") (which closing price hurdle has been achieved) (the "Price Condition"). The portion of the award subject to satisfaction of the Price Condition is scheduled to vest in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022. Upon the closing of the IPO, vesting of the portion of the option award subject to condition (ii) was tied only to the passage of time and the market price of the Company's securities and thus, 50% of the option award became reportable. F3 · derivative.exercise_date: (Continued from Footnote 2) The Original Form 4 failed to report the portion of the option award that became reportable upon the closing of the Company's IPO. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.